What You Should Know:
– Mindera Health, a leading developer of precision medicine solutions for dermatology, raises $14M convertible note financing led by Mountain Group Partners.
– The funding will accelerate the commercialization of Mindera’s flagship product, Mind.Px™, a groundbreaking test that predicts patient response to psoriasis treatments.
Revolutionizing Psoriasis Treatment
Mind.Px™ is a proprietary biomarker test that analyzes a patient’s skin sample to determine the optimal treatment path for psoriasis. By identifying the most effective drug class upfront, Mind.Px™ can significantly reduce the time and cost associated with trial-and-error treatment approaches.
“We are excited to continue our partnership with Mindera and remain committed to improving patient outcomes in psoriasis with Mind.Px™,” said Joe Cook, III, Managing Director at Mountain Group Partners and Chairman of Mindera Health. “We believe the company’s novel, patented approach to precision therapy selection has the potential to address a myriad of unmet needs across the dermatological treatment landscape.”
